Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI Deferred research and development funding liability, current

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept dnli:DeferredLiabilityCapitalizedResearchAndDevelopmentCostsCurrent.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Denali Therapeutics Inc.'s deferred research and development funding liability, current?
Denali Therapeutics Inc. (DNLI) reported deferred research and development funding liability, current of $15.1M in Q1 2026.
How has Denali Therapeutics Inc.'s deferred research and development funding liability, current changed year-over-year?
Denali Therapeutics Inc.'s deferred research and development funding liability, current decreased by 12.9% year-over-year, from $17.34M to $15.1M.